TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$15.72
-0.12 (-0.76%)
▼
5d:
+0.38%
30d:
-3.26%
90d:
-12.86%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Jul 30, 2026
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TAK appears deeply undervalued. Market expects -0.8% annual earnings decline despite 330% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: TAK appears deeply undervalued. Market expects -0.8% annual earnings decline despite 330% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
31.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $15.72, which is considered fair relative to its 30-day fair value range of $15.41 to $16.26. From a valuation perspective, the stock is trading at a discount (Forward PE: 0.2) compared to its historical average (0.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.8% over the next few years. This pessimistic expectation contrasts with the company's recent 330.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TAK is in a strong downtrend. The price is currently testing key support at $15.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.60 (+31.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TAK is in a strong downtrend. The price is currently testing key support at $15.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TAK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.60 (+31.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$15.41 -
$16.26
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.1% below Wall St target ($20.60)
Trading Range Analysis
30-Day Trading Range
$15.41 -
$16.26
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$15.34
Resistance Level
$16.03
Current Trend
Strong Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.17
Wall Street Target
$20.60
(+31.1%)
Revenue Growth (YoY)
3.9%
Earnings Growth (YoY)
330.2%
Profit Margin
-3.4%
Valuation Discount vs History
-0.8% cheaper
PE vs Historical
0.2 vs 0.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.8%
(market-implied from PE analysis)
1-Year Target
$15.59
(-1%)
2-Year Target
$15.47
(-2%)
3-Year Target
$15.35
(-2%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
$18.54
(+18%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 93.0%)
$6981.89
(+44314%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$53.06
(+238%)
Bear:
(PE: 0.1, Growth: 93.0%)
$45.10
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (0x PE) as earnings recover.
Trailing PE: 41.68 | Current EPS (TTM): $0.37
Bull Case
$33.92
(+117%)
Analyst growth 100.0%, PE expands to 45.8
Base Case
$30.84
(+97%)
Market implied 100.0%, PE stable at 41.7
Bear Case
$10.49
(-33%)
Severe decline -20.0%, PE contracts to 35.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 0.2 to 0.2
Stabilization Target:
$19.00
(+20.8%)
PE Expansion Potential:
+20.8%
Share & Embed Analysis
Last updated: June 24, 2026 5:17 PM ET
Data refreshes hourly during market hours. Next update: 6:17 PM
Data refreshes hourly during market hours. Next update: 6:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 60 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 57 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 59 HOLD |
